Latest News - Eyegate Pharmaceuticals

Tuesday, August 01, 2017 | Clinical Trials, Eyegate Pharmaceuticals

EyeGate Pharma Enrolls First Patient in Phase 2b Clinical Study of EGP-437 for Cataract Surgery

EyeGate Pharmaceuticals announced that the first patient was enrolled in the company’s phase 2b clinical trial of its EGP-437 combination product. The EyeGate II Delivery System and EGP-437 comb…

Read the full story

Monday, May 22, 2017 | Earnings & Financials, Eyegate Pharmaceuticals

EyeGate Receives Milestone Payment from Valeant for EGP-437 for Postoperative Ocular Inflammation and Pain

EyeGate Pharmaceuticals announced that it has received its first development milestone from a subsidiary of Valeant under the company's license agreement with Valeant, pursuant to which EyeGate …

Read the full story

Thursday, May 04, 2017 | Clinical Trials, Eyegate Pharmaceuticals

EyeGate Submits IDE Filing for Second Pilot Study of Ocular Bandage Gel

EyeGate Pharmaceuticals announced that it has submitted an investigational device exemption (IDE) for the lead product in its cross-linked thiolated carboxymethyl hyaluronic acid (CMHA-S) platform, Ey…

Read the full story

Monday, March 13, 2017 | Management/Leadership, Eyegate Pharmaceuticals

EyeGate Pharma Appoints Daniel S. Durrie, MD, and Randall J. Olson, MD, to Scientific Advisory Board

EyeGate Pharmaceuticals announced the appointment of two leading ophthalmology experts, Daniel S. Durrie, MD, and Randall J. Olson, MD, to its Scientific Advisory Board. Drs. Durrie and Olson will wor…

Read the full story

Tuesday, February 21, 2017 | Acquisitions/Mergers, Eyegate Pharmaceuticals, Valeant

Valeant and Eyegate Enter into Licensing Agreement for EyeGate II Delivery System and EGP-437 Combination Product

Valeant Pharmaceuticals International and EyeGate Pharmaceuticals announced that they have entered into an exclusive, worldwide licensing agreement through which EyeGate has granted a subsidiary of Va…

Read the full story

Monday, December 05, 2016 | Clinical Trials, Eyegate Pharmaceuticals

EyeGate Reports Positive Data from Third Stage of Phase 1b/2a Clinical Trial of EGP-437 in Cataract Surgery Patients

EyeGate Pharmaceuticals announced promising data from the third stage of its phase 1b/2a trial assessing lead product candidate, iontophoretic EGP-437, for the treatment of ocular inflammation and pai…

Read the full story

Thursday, November 17, 2016 | Miscellaneous, Eyegate Pharmaceuticals

FDA Confirms a 510(k) De Novo Path for EyeGate's Ocular Bandage Gel

EyeGate Pharmaceuticals announced that, following a presubmission meeting with the FDA, it plans to pursue US regulatory clearance of its EyeGate Ocular Bandage Gel via the De Novo 510(k) pathway. Eye…

Read the full story

Monday, August 01, 2016 | Clinical Trials, Eyegate Pharmaceuticals

EyeGate Announces Positive Topline Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Postoperative Inflammation and Pain in Cataract Surgery Patients

EyeGate Pharmaceuticals announced positive data from its phase 1b/2a trial assessing its lead product candidate, iontophoretic EGP-437, in the treatment of postoperative ocular inflammation and pain i…

Read the full story

Wednesday, June 01, 2016 | Cataract Surgery, Clinical Trials, Eyegate Pharmaceuticals

EyeGate Announces Interim Data from Clinical Trial of EGP-437 for Treatment of Inflammation and Pain After Cataract Surgery

EyeGate Pharmaceuticals announced interim data from its phase 1b/2a trial evaluating its lead product candidate, iontophoretic EGP-437, in the treatment of ocular inflammation and pain in cataract sur…

Read the full story

Tuesday, April 26, 2016 | Clinical Trials, Eyegate Pharmaceuticals

EyeGate Pharma to Present Four Posters at ARVO 2016 Annual Meeting Supporting Development of CMHA-S

EyeGate Pharmaceuticals announced that four abstracts supporting the ongoing development of its proprietary technology cross-linked hyaluronic acid polymer (CMHA-S) have been accepted for poster prese…

Read the full story

Wednesday, March 09, 2016 | Acquisitions/Mergers, Eyegate Pharmaceuticals, Jade Therapeutics

EyeGate Pharma Acquires Jade Therapeutics

Eyegate Pharmaceuticals announced that it has acquired Jade Therapeutics, a privately-held company developing locally administered, polymer-based products designed to treat poorly-served ophthalmic in…

Read the full story

Tuesday, January 19, 2016 | Clinical Trials, Eyegate Pharmaceuticals

EyeGate Pharma Enrolls First Patient in Confirmatory Phase 3 Clinical Trial EGP-437-006 for Non-Infectious Anterior Uveitis

Eyegate Pharmaceuticals announced that the first patient was enrolled in the company’s confirmatory phase 3 clinical trial of its EGP-437 combination product, the company’s lead product, i…

Read the full story

Thursday, October 15, 2015 | Miscellaneous, Eyegate Pharmaceuticals

EyeGate Pharma Receives USPTO Notice of Allowance for Next Generation of Proprietary Iontophoretic Delivery System

Eyegate Pharmaceuticals announced that it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for a patent application related to its EyeGate II Delivery System. The pat…

Read the full story

Friday, July 24, 2015 | Miscellaneous, Eyegate Pharmaceuticals

EyeGate Pharma Receives USPTO Notice of Allowance for Proprietary Dexamethasone Phosphate Formulation

Eyegate Pharmaceuticals announced that it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for a patent application related to its lead product candidate, EGP-437. Th…

Read the full story

Friday, July 10, 2015 | Partnerships, Eyegate Pharmaceuticals, Valeant

EyeGate Signs Licensing Agreement with Valeant Pharmaceuticals for EGP-437 Combination Product in Uveitis

Eyegate Pharmaceuticals announced that it has entered into an exclusive, worldwide licensing agreement with a subsidiary of Valeant Pharmaceuticals International through which EyeGate has granted Vale…

Read the full story
Load More